NCT02691533View on ClinicalTrials.gov

To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Chronic Liver Failure
Interventions
DRUG

ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)

DRUG

ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)

DRUG

No Lipid Emulsion/Placebo

Trial Locations (1)

110070

Institute of liver and Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT02691533 - To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure | Biotech Hunter | Biotech Hunter